VCU Massey researchers discover TAF2 gene plays a pivotal role in HCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Devanand Sarkar and a team of scientists at VCU Massey Comprehensive Cancer Center have discovered that the gene TAF2 plays a pivotal role in the growth of hepatocellular carcinoma. The researchers found that TAF2 is overexpressed in HCC patients compared to individuals with healthy livers, and that TAF2 regulates the survival of hepatocytes—the functional cells of the liver—and tumor formation. Their study—recently published in the journal Hepatology also demonstrates that TAF2 cooperates with the MYC gene, another known major driver of cancer, to accelerate tumor growth.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) from Bristol Myers Squibb for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma, based on results from the phase III CheckMate-9DW trial. The CHMP opinion will now be reviewed by the European Commission.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login